Search results for " Ly"

showing 10 items of 2487 documents

Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

2021

Not Available

OncologyMalechronic B cell leukemiachronic lymphocytic leukemia; ibrutinib; 4-factor score; prognosis.Datasets as TopicSeverity of Illness Indexchemistry.chemical_compoundPiperidinesRetrospective analysisMulticenter Studies as TopicChronicLeukemiaHematologyMiddle AgedPrognosisLymphocyticProgression-Free SurvivalIbrutinibFemalemedicine.medical_specialtyreal-word studyFactor scoreAntineoplastic AgentsAdenine; Aged; Antineoplastic Agents; Datasets as Topic; Female; Follow-Up Studies; Humans; Leukemia Lymphocytic Chronic B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Piperidines; Prognosis; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival AnalysisRisk AssessmentNOibrutinibInternal medicineSeverity of illnessmedicineHumansProgression-free survivalProtein Kinase InhibitorsSurvival analysisAgedProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelAdenineB-CellReproducibility of ResultsRetrospective cohort studyAdenine; Aged; Antineoplastic Agents; Datasets as Topic; Female; Follow-Up Studies; Humans; Leukemia Lymphocytic Chronic B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Piperidines; Prognosis; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Survival Analysis; Severity of Illness IndexLeukemia Lymphocytic Chronic B-CellSurvival AnalysisSettore MED/15 - MALATTIE DEL SANGUEchemistrybusinesschronic lymphocytic leukaemiaFollow-Up Studies
researchProduct

Occupational exposure to endocrine disruptors and lymphoma risk in a multi-centric European study

2015

Background: Incidence rates of lymphoma are usually higher in men than in women, and oestrogens may protect against lymphoma. Methods: We evaluated occupational exposure to endocrine disrupting chemicals (EDCs) among 2457 controls and 2178 incident lymphoma cases and subtypes from the European Epilymph study. Results: Over 30 years of exposure to EDCs compared to no exposure was associated with a 24% increased risk of mature B-cell neoplasms (P-trend=0.02). Associations were observed among men, but not women. Conclusions: Prolonged occupational exposure to endocrine disruptors seems to be moderately associated with some lymphoma subtypes. © 2015 Cancer Research UK. All rights reserved.

OncologyMaleendocrine systemCancer Researchmedicine.medical_specialtyanimal structuresLymphomaEpidemiologyJob-exposure matrixchemicalsEndocrine Disruptors03 medical and health sciences0302 clinical medicineSex FactorsSex factorsRisk FactorsInternal medicinehemic and lymphatic diseasesOccupational ExposuremedicineOccupational exposure - endocrine disrupting chemicals (EDCs) - lymphoma riskEndocrine systemHumansurogenital systembusiness.industryIncidence (epidemiology)IncidenceCase-control studynutritional and metabolic diseasespesticidesmedicine.disease030210 environmental & occupational health3. Good healthLymphomaEuropeOccupational DiseasessolventsOncologyMulticenter study030220 oncology & carcinogenesisCase-Control StudiesImmunologyleukaemiaalkylphenolsFemaleOccupational exposurebusinesshormones hormone substitutes and hormone antagonists
researchProduct

CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >5…

2018

Reduced-intensity conditioning (RIC) and T cell depletion (TCD) through CD34+ cell selection without the use of post-transplantation immunosuppression are 2 strategies used to reduce nonrelapse mortality (NRM) in older patients after allogeneic hematopoietic cell transplantation (allo-HCT). To compare the efficacy of the RIC and TCD approaches, we evaluated the outcomes of patients age >50 years with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) who underwent allo-HCT from an HLA-matched donor with one of these strategies. Baseline characteristics were comparable in the patients receiving TCD (n = 204) and those receiving RIC (n = 151), except for a higher proportion o…

OncologyMalemedicine.medical_specialtyTransplantation Conditioningmedicine.medical_treatmentCD34GVHDGraft vs Host DiseaseAntigens CD34Lymphocyte Depletion03 medical and health sciencesMyelogenous0302 clinical medicineRecurrencehemic and lymphatic diseasesInternal medicinemedicineHumansTransplantation HomologousIn patientAgedRetrospective StudiesTransplantationHematopoietic cellbusiness.industryRICHematopoietic Stem Cell TransplantationImmunosuppressionT-cell depletionHematologyAllogeneic hematopoietic cell transplantationMiddle AgedMyeloablative Agonistsmedicine.diseaseTransplantationLeukemiaLeukemia Myeloid Acute030220 oncology & carcinogenesisMyelodysplastic SyndromesFemalebusinessT cell depletion030215 immunology
researchProduct

Predicting survival in node-positive prostate cancer after open, laparoscopic or robotic radical prostatectomy: A competing risk analysis of a multi-…

2016

Objectives: To investigate cancer-specific mortality and other-cause mortality in prostate cancer patients with nodal metastases. Methods: The study included 411 patients treated with radical prostatectomy and pelvic lymph node dissection for prostate cancer with lymph node metastases at 10 tertiary care centers between 1995 and 2014. Kaplan–Meier analyses were used to assess cancer-specific mortality-free survival rates at 8 years' follow up in the overall population, and after stratifying patients according to clinical and pathological parameters. Uni- and multivariable competing risk Cox regression analyses were used to assess cancer-specific mortality and other-cause mortality. Finally,…

OncologyMalemedicine.medical_treatment030232 urology & nephrologyProstate cancer0302 clinical medicineRobotic Surgical ProceduresLymph nodeeducation.field_of_studyProstatectomyMortality rateLymph NodePrognosiscancer-specific mortality competing risk analysis lymph node metastases other-cause mortality radical prostatectomylymph node metastaseDissectionmedicine.anatomical_structure030220 oncology & carcinogenesisLymphatic MetastasisLymphSurvival Analysicancer-specific mortality; competing risk analysis; lymph node metastases; other-cause mortality; radical prostatectomycancer-specific mortality; competing risk analysis; lymph node metastases; other-cause mortality; radical prostatectomy; Urologyother-cause mortalityHumanlymph node metastasesRiskmedicine.medical_specialtyRobotic Surgical ProcedurePrognosiUrologyPopulationUrologycancer-specific mortality03 medical and health sciencesInternal medicinemedicineHumanseducationcompeting risk analysiProstatectomybusiness.industryProportional hazards modelcompeting risk analysisProstatic NeoplasmsLymphatic MetastasiProstate-Specific Antigenmedicine.diseaseSurvival Analysisradical prostatectomyProstatic NeoplasmLymph Node ExcisionLaparoscopyLymph Nodesbusiness
researchProduct

The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy includi…

2015

Part of this study has been reported as an oral presentation at the EHA Meeting in Vienna 2015.

OncologyMalemedicine.medical_treatmentarray-based comparative genomic hybridization (aCGH)Intensive chemotherapyKaplan-Meier EstimateBioinformatics0302 clinical medicinerituximabAntineoplastic Combined Chemotherapy ProtocolsYoung adultComparative Genomic HybridizationGenomeArray-based comparative genomic hybridizationBurkitt lymphomaHigh-Throughput Nucleotide SequencingHematologyMiddle AgedPrognosisBurkitt Lymphomahumanities3. Good healthTreatment Outcome030220 oncology & carcinogenesisoutcomeRituximabFemaleRituximabmedicine.drugAdultmedicine.medical_specialtyAdolescenteducationBiologyNext-generation sequencing outcome03 medical and health sciencesYoung AdultInternal medicinemedicineHumansIn patientAgedChromosome AberrationsChemotherapymedicine.diseaseGNA13Lymphomastomatognathic diseasesnext-generation sequencing030215 immunologyComparative genomic hybridization
researchProduct

Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable res…

2021

Programa para el Tratamiento de Hemopatias Malignas (PETHEMA) Group (Spanish Society of Hematology, SEHH).

OncologyMalep13)/TCF3-PBX1Neoplasm ResidualOncogene Proteins FusionCytogenetic alterationsmedicine.medical_treatmentDiseaseTranslocation Genetichemic and lymphatic diseasesAntineoplastic Combined Chemotherapy Protocolst(1;19)(q23;p13)/TCF3-PBX1Cumulative incidenceCitogenètica humanaNeoplasm MetastasisLeucèmia limfoblàstica - TractamentHuman cytogeneticsLeukemiaAcute lymphoblastic leukaemiaRemission InductionLeucèmiaDisease ManagementHematologyMiddle AgedPrognosisHaematopoiesismedicine.anatomical_structureTreatment OutcomeChromosomes Human Pair 1TCF3:Other subheadings::Other subheadings::/therapy [Other subheadings]FemaleStem cell:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Lymphoid::Precursor Cell Lymphoblastic Leukemia-Lymphoma::Precursor B-Cell Lymphoblastic Leukemia-Lymphoma [DISEASES]Adultmedicine.medical_specialtyPronòstic mèdicAdolescentQuimioteràpia combinadaYoung AdultInternal medicinePrecursor B-Cell Lymphoblastic Leukemia-LymphomamedicineAdultsHumansB cell19)(q23Neoplasm Staging:neoplasias::neoplasias por tipo histológico::leucemia::leucemia linfoide::leucemia-linfoma linfoblástico de células precursoras::leucemia-linfoma linfoblástico de células B precursoras [ENFERMEDADES]business.industryacute lymphoblastic leukaemia adults cytogenetic alterations prognosis t(1:Otros calificadores::Otros calificadores::/terapia [Otros calificadores]ImmunotherapyChromosome BandingTransplantationt(1Avaluació de resultats (Assistència sanitària)businessChromosomes Human Pair 19British journal of haematologyReferences
researchProduct

A Novel System for Semiautomatic Sample Processing in Chronic Myeloid Leukaemia: Increasing Throughput without Impacting on Molecular Monitoring at T…

2021

Molecular testing of the BCR-ABL1 transcript via real-time quantitative-polymerase-chain-reaction is the most sensitive approach for monitoring the response to tyrosine-kinase-inhibitors therapy in chronic myeloid leukaemia (CML) patients. Each stage of the molecular procedure has been standardized and optimized, including the total white blood cells (WBCs) and RNA isolation methods. Here, we compare the performance of our current manual protocol to a newly semiautomatic method based on the Biomek i-5 Automated Workstations integrated with the CytoFLEX Flow Cytometer, followed by the automatic QIAsymphony system to facilitate high-throughput processing samples and reduce the hands-on time a…

OncologyMedicine (General)medicine.medical_specialtyBCR-ABL1/ABL1Q-PCRbusiness.industrychronic myeloid leukaemiaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)SARS-CoV-2 infectionClinical BiochemistrySample processingmolecular responseBCR-ABL1/ABL1ISChronic myeloid leukaemiaArticle<i>BCR-ABL1/ABL1<sup>IS</sup></i>R5-920Real-time polymerase chain reactionInternal medicinehemic and lymphatic diseasesMolecular ProcedureISmedicineRNA extractionbusinessDiagnostics
researchProduct

Rituximab in the treatment of non-Hodgkin&amp;rsquo;s lymphoma

2008

Beate Hauptrock, Georg HessHematology/Oncology, Johannes Gutenberg-University, Mainz, GermanyAbstract: Besides traditional cytostatic drugs the introduction of monoclonal antibodies has substantially influenced current treatment concepts of non-Hodgkin&amp;rsquo;s lymphoma (NHL). &amp;nbsp;Rituximab, a monoclonal anti-CD20 chimeric antibody, now has been widely evaluated in the various B-cell lymphatic neoplasms. Large phase III studies helped to prove the value of this drug in follicular lymphoma as part of induction or relapse treatment as well as maintenance treatment. The addition of rituximab to the well established CHOP regimens has increased achievable cure rates in diffuse large cel…

OncologyMedicine (General)medicine.medical_specialtybusiness.industryFollicular lymphomaCHOPmedicine.diseaseLymphomaNon-Hodgkin's lymphomaR5-920immune system diseasesChemoimmunotherapyhemic and lymphatic diseasesInternal medicineMonoclonalImmunologymedicineMantle cell lymphomaRituximabbusinessmedicine.drugBiologics: Targets &amp; Therapy
researchProduct

Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature res…

2014

Summary Salvage therapy followed by high-dose therapy (HDT) remains a mainstay for patients with relapsed lymphoma, however no optimal regimen has been defined. Here we report on the results of R-DexaBEAM (rituximab, dexamethasone, carmustine, etoposide, cytarabine, melphalan) followed by HDT. Patients aged 18–65 years, Eastern Cooperative Oncology Group performance score 0–2, with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) were eligible. R-Dexa-BEAM was given for two cycles followed by stem cell mobilization and HDT. Primary endpoint of the trial was progression-free-survival (PFS). One hundred and three patients were included: aggressive NHL (aNHL): diffuse large B-cell lymphom…

OncologyMelphalanAdultMalemedicine.medical_specialtyLymphoma B-CellFollicular lymphomaSalvage therapyKaplan-Meier EstimateDexamethasoneDrug Administration ScheduleAntibodies Monoclonal Murine-DerivedYoung Adultimmune system diseasesRecurrencehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAutologous transplantationHumansProspective StudiesMelphalanEtoposideAgedEtoposideSalvage TherapyDose-Response Relationship Drugbusiness.industryPatient SelectionRemission InductionCytarabineHematologyMiddle Agedmedicine.diseaseCarmustineHematopoietic Stem Cell MobilizationLymphomaSurgeryMantle cell lymphomaRituximabFemalebusinessRituximabmedicine.drugBritish journal of haematology
researchProduct

Minimum tolerable interval of 90yttrium ibritumomab-tiuxetan to autologous stem cell transplantation after high-dose chemotherapy with carmustin, eto…

2012

6543 Background: High-dose therapy and autologous stem cell transplantation (ASCT) in patients (pts) with aggressive B-NHL failing from immunochemotherapy including rituximab show poor outcome with 3y PFS of 39% (Gisselbrecht et al. JCO 2010). Combining BEAM with 90yttrium ibritumomab tiuxetan is a promising option to enhance the efficacy of the high-dose regimen. Methods: Pts without disease progression during salvage therapy of relapsed or refractory CD20+ aggressive B-NHL were included in this prospective, multicenter, phase I/II trial. Primary endpoint was the maximum tolerated dose of 90Yttrium ibritumomab tiuxetan given as close as possible to ASCT defined as &lt;2 pts with dose limi…

OncologyMelphalanCancer Researchmedicine.medical_specialtybusiness.industryIbritumomab tiuxetanAutologous stem-cell transplantationOncologyRefractoryInternal medicinemedicineB-Cell Non-Hodgkin LymphomaCytarabineRituximabbusinessEtoposidemedicine.drugJournal of Clinical Oncology
researchProduct